Article
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Gut - 1 Apr 2019
Shiha Gamal, Esmat Gamal, Hassany Mohamed, Soliman Reham, Elbasiony Mohamed, Fouad Rabab, Elsharkawy Aisha, Hammad Radi, Abdel-Razek Wael, Zakareya Talaat, Kersey Kathryn, Massetto Benedetta, Osinusi Anu, Lu Sophia, Brainard Diana M, McHutchison John G, Waked Imam, Doss Wahid
Abstract excerpt
OBJECTIVE: We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. DESIGN: In this open-label, multicentre, phase III study, treatment-naive patients were randomised to receive 8 or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.